Ozempic vs Saxenda 2026: Weight Loss Efficacy Compared
Ozempic (semaglutide) and Saxenda (liraglutide) are both GLP-1 receptor agonists for weight loss, but Ozempic is approximately 2x more potent, requires weekly dosing versus daily injections for Saxenda, and demonstrates superior weight loss results (15% vs 5-6% body weight reduction) in clinical trials.
Ozempic (semaglutide)
Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.
Patients seeking maximum weight loss results, those preferring weekly dosing, and individuals with comorbid cardiovascular disease or type 2 diabetes.
Saxenda (Liraglutide)
GLP-1 receptor agonist injection for weight loss; administered daily with established 7-year safety record.
Patients with semaglutide contraindications, those seeking a gentler side effect profile, or individuals preferring to use a medication with 7+ years of weight-loss-specific real-world data.
Quick Answer
AI SummaryOzempic (semaglutide) and Saxenda (liraglutide) are both GLP-1 receptor agonists for weight loss, but Ozempic is approximately 2x more potent, requires weekly dosing versus daily injections for Saxenda, and demonstrates superior weight loss results (15% vs 5-6% body weight reduction) in clinical trials.
Our Verdict
AI-assistedChoose Ozempic/Wegovy if you prioritize superior weight loss results (2-3x higher), prefer once-weekly dosing for convenience, and want potentially lower out-of-pocket costs. Choose Saxenda if you have contraindications to semaglutide, are medically managed by an endocrinologist familiar with liraglutide, or prefer a longer track record in the weight-loss market (FDA-approved 7 years earlier).
Was this verdict helpful?
Choose Ozempic (semaglutide) if
Best pickPatients seeking maximum weight loss results, those preferring weekly dosing, and individuals with comorbid cardiovascular disease or type 2 diabetes.
Choose Saxenda (Liraglutide) if
Patients with semaglutide contraindications, those seeking a gentler side effect profile, or individuals preferring to use a medication with 7+ years of weight-loss-specific real-world data.
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Active Ingredient:Semaglutide (GLP-1 agonist) vs Liraglutide (GLP-1 agonist)
- Average Weight Loss (% body weight):✓ Ozempic (semaglutide) wins(15% over 68 weeks vs 5-6% over 56 weeks)
- Dosing Frequency:✓ Ozempic (semaglutide) wins(Once weekly injection vs Daily injection)
Key Facts & Figures
26 numeric metrics compared
| Metric | Ozempic (semaglutide) | Saxenda (Liraglutide) | Ratio |
|---|---|---|---|
| Dosing Frequency(times per week) | 1x weekly | 7x weekly (daily) | |
| Time to Maximum Dose(weeks) | 4 weeks | 5 weeks | |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | 2014 | |
| Average Monthly Cost (Uninsured)(USD) | $1,100 | $1,500 | |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | 56 weeks (SCALE) | |
| FDA Approval Year | 2017 | — | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — | — |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | — | — |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | — | — |
| Nausea Incidence Rate(%) | 25-40% | 26% | |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes) | — | — |
| CVOT Cardiovascular Risk Reduction(%) | 26% | — | — |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | — | — |
| Maximum Weight Loss at Highest Approved Dose(%) | 22% | — | — |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8% | — | — |
| Half-Life Duration(hours) | 168 hours (7 days) | — | — |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | — | — |
| Time to Reach Steady State(weeks) | 4-5 weeks | — | — |
| GI Side Effect Incidence Rate(%) | 32% | — | — |
| Years on Market(years) | 11 years (since 2013) | — | — |
| Injection Frequency | Once weekly | — | — |
| Average Body Weight Loss(%) | 15% | — | — |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6) | 13% (LEADER trial) | |
| Maximum Approved Dose(mg) | 2.4 mg weekly | — | — |
| Years Since FDA Approval(years) | 7 years (2017) | — | — |
| Nausea Incidence in Trials(%) | 25-39% | — | — |
Sourced from publicly available data ·
Key Differences
7 attributes compared head-to-head
- Semaglutide (GLP-1 agonist)Active IngredientLiraglutide (GLP-1 agonist)
- 15% over 68 weeks(winner)Average Weight Loss (% body weight)5-6% over 56 weeks
- Once weekly injection(winner)Dosing FrequencyDaily injection
- 4 weeks(winner)Time to Reach Max Dose5 weeks
- 26-39% mild-moderate nauseaGastrointestinal Side Effects Rate20-32% mild-moderate nausea(winner)
- Wegovy (2021) - approved for weight managementFDA Approval for Weight Loss (Indication)Saxenda (2014) - approved for weight loss
- $900-1,500 USD(winner)Average Monthly Out-of-Pocket Cost (uninsured)$1,200-1,800 USD
- Active Ingredient
Ozempic (semaglutide)
Semaglutide (GLP-1 agonist)
Saxenda (Liraglutide)
Liraglutide (GLP-1 agonist)
- Average Weight Loss (% body weight)
Ozempic (semaglutide)
15% over 68 weeks(winner)
Saxenda (Liraglutide)
5-6% over 56 weeks
- Dosing Frequency
Ozempic (semaglutide)
Once weekly injection(winner)
Saxenda (Liraglutide)
Daily injection
- Time to Reach Max Dose
Ozempic (semaglutide)
4 weeks(winner)
Saxenda (Liraglutide)
5 weeks
- Gastrointestinal Side Effects Rate
Ozempic (semaglutide)
26-39% mild-moderate nausea
Saxenda (Liraglutide)
20-32% mild-moderate nausea(winner)
- FDA Approval for Weight Loss (Indication)
Ozempic (semaglutide)
Wegovy (2021) - approved for weight management
Saxenda (Liraglutide)
Saxenda (2014) - approved for weight loss
- Average Monthly Out-of-Pocket Cost (uninsured)
Ozempic (semaglutide)
$900-1,500 USD(winner)
Saxenda (Liraglutide)
$1,200-1,800 USD
Full Comparison
| Attribute | Ozempic (semaglutide) | Saxenda (Liraglutide) |
|---|---|---|
| Average Weight Loss(%) | 15%(winner) | 5.6% |
| Time to Maximum Dose(weeks) | 4 weeks(winner) | 5 weeks |
| Maximum Weight Loss at Highest Approved Dose(%) | 22% | — |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8% | — |
| Average Body Weight Loss(%) | 15% | — |
| Dosing Frequency(times per week) | 1x weekly(winner) | 7x weekly (daily) |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | 2014(winner) |
| Average Monthly Cost (Uninsured)(USD) | $1,100(winner) | $1,500 |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | — |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | 56 weeks (SCALE) |
| FDA Approval Year | 2017 | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — |
| Maximum Approved Dose(mg) | 2.4 mg weekly | — |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | — |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | — |
| Nausea Incidence Rate(%) | 25-40% | 26%(winner) |
| GI Side Effect Incidence Rate(%) | 32% | — |
| Nausea Incidence in Trials(%) | 25-39% | — |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes) | — |
| CVOT Cardiovascular Risk Reduction(%) | 26% | — |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | — |
| Half-Life Duration(hours) | 168 hours (7 days) | — |
| Time to Reach Steady State(weeks) | 4-5 weeks | — |
| Years on Market(years) | 11 years (since 2013) | — |
| Injection Frequency | Once weekly | — |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6)(winner) | 13% (LEADER trial) |
| Years Since FDA Approval(years) | 7 years (2017) | — |
Pros & Cons
10 pros·6 cons across both
Ozempic (semaglutide)
Pros
- Superior weight loss efficacy: 15% average body weight reduction in STEP trials
- Once-weekly injection increases adherence vs daily regimens
- Rapid dose escalation: reaches therapeutic dose in 4 weeks
- Additional cardiovascular benefits including 26% reduction in major adverse events in SELECT trial
- Lower out-of-pocket costs than Saxenda ($900-1,500 monthly vs $1,200-1,800)
Cons
- Higher nausea incidence (26-39% vs 20-32%) affecting treatment tolerance
- Risk of pancreatitis and gallbladder complications reported in post-market surveillance
- Contraindicated in personal/family history of medullary thyroid cancer or MEN syndrome
Saxenda (Liraglutide)
Pros
- Longer clinical track record: FDA-approved for weight loss since 2014 with extensive real-world data
- Lower gastrointestinal side effect profile (20-32% nausea vs 26-39%)
- Established dosing protocols in weight loss clinics and bariatric medicine centers
- Effective for patients who cannot tolerate semaglutide
- Same GLP-1 mechanism with proven cardiovascular benefits in LEADER trial
Cons
- Significantly lower weight loss: 5-6% body weight vs 15% with semaglutide (66% less effective)
- Daily injection burden reduces adherence compared to weekly alternatives
- Higher out-of-pocket costs ($1,200-1,800 monthly uninsured)
Frequently Asked Questions
5 questions
Semaglutide (Ozempic) is approximately 2x more potent at the GLP-1 receptor compared to liraglutide (Saxenda). Clinical evidence from the STEP trials shows semaglutide produces 15% average weight loss versus 5-6% with liraglutide at equivalent therapeutic doses. The higher receptor affinity and longer half-life (7 days vs 13 hours) of semaglutide contributes to superior appetite suppression and metabolic effects.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
- W
Ozempic (semaglutide) on Wikipedia (opens in new tab)
Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.
- W
Saxenda (Liraglutide) on Wikipedia (opens in new tab)
GLP-1 receptor agonist injection for weight loss; administered daily with established 7-year safety record.
Related Comparisons
12 more to explore
Ozempic vs Zepbound
healthOzempic vs Victoza
healthOzempic vs Victoza
healthYoga vs Pilates
healthIbuprofen vs Acetaminophen
healthInvisalign vs Traditional Braces
healthWhey Protein vs Casein Protein
healthCrossFit vs Gym Training
healthFlu Shot vs COVID Vaccine
healthOrganic Food vs Non-Organic Food
healthTherapy vs Medication
healthMeditation vs Yoga
health
Related Articles
1 article
Explore More
Related comparisons and categories